Individual-patient BC-BM pair analysis using the MCP counter platform showed that the scores of most immune-cell subsets—T cells (p < 0.001), CD8+ T cells (p < 0.001), cytotoxicity score (p < 0.001), B cells (p < 0.001), the ratio of macrophages to monocytes (p = 0.001), monocytes (p = 0.001) and endothelial cells (p = 0.001)—were significantly lower in BCBM than primary BC (Figure 3c). The gene discussed is CD8A; the disease is breast cancer.